{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:04:50Z","timestamp":1780092290454,"version":"3.54.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Kedrion S.p.A.","award":["1000128"],"award-info":[{"award-number":["1000128"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.intimp.2016.12.030","type":"journal-article","created":{"date-parts":[[2017,1,7]],"date-time":"2017-01-07T19:03:41Z","timestamp":1483815821000},"page":"38-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Rapid infusions of human normal immunoglobulin 50g\/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia"],"prefix":"10.1016","volume":"44","author":[{"given":"Giuseppe","family":"Spadaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Alberto Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Lamacchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Milito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bacchiarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Carrai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Hibbeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Speckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Guarnieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Bongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Quinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2016.12.030_bb0005","author":"WHO"},{"key":"10.1016\/j.intimp.2016.12.030_bb0010","author":"WHO"},{"issue":"8","key":"10.1016\/j.intimp.2016.12.030_bb0015","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/eji.201444700","article-title":"European consensus proposal for immunoglobulin therapies","volume":"44","author":"Sewell","year":"2014","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2016.12.030_bb0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.intimp.2016.12.030_bb0025","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2217\/imt.14.54","article-title":"Immunoglobulin replacement therapy for primary immunodeficiencies","volume":"6","author":"Peter","year":"2014","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.intimp.2016.12.030_bb0030","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jaci.2008.08.033","article-title":"Intravenous immunoglobulin: adverse reactions and management","volume":"122","author":"Bonilla","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2016.12.030_bb0035","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/vox.12275","article-title":"An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease","volume":"109","author":"Kriv\u00e1n","year":"2015","journal-title":"Vox Sang."},{"issue":"3","key":"10.1016\/j.intimp.2016.12.030_bb0040","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s10875-010-9373-x","article-title":"Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates","volume":"30","author":"Sleasman","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.intimp.2016.12.030_bb0045","author":"European Commission"},{"key":"10.1016\/j.intimp.2016.12.030_bb0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13223-015-0092-y","article-title":"Health-related quality of life in patients with primary immunodeficiency disease","volume":"11","author":"Jiang","year":"2015","journal-title":"Allergy, Asthma Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2016.12.030_bb0055","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ajh.20992","article-title":"Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura","volume":"83","author":"McMillan","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2016.12.030_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.08.027","article-title":"Physical health conditions and quality of life in adults with primary immune deficiency diagnosed during childhood: a CEREDIH study","author":"Barlogis","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2016.12.030_bb0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/PPA.S58040","article-title":"Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies","volume":"8","author":"Kuburovic","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.intimp.2016.12.030_bb0070","first-page":"23","article-title":"Health-related quality of life in primary immune deficient patients","volume":"5","author":"Mozaffari","year":"2006","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.intimp.2016.12.030_bb0075","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fimmu.2014.00605","article-title":"Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies","volume":"5","author":"Tabolli","year":"2014","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2016.12.030_bb0080","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10875-007-9075-1","article-title":"Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency","volume":"27","author":"Quinti","year":"2007","journal-title":"J. Clin. Immunol."},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2016.12.030_bb0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2249.2011.04390.x","article-title":"Key aspects for successful immunoglobulin therapy of primary immunodeficiencies","volume":"164","author":"Cunningham-Rundles","year":"2011","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2016.12.030_bb0090","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s10875-016-0279-0","article-title":"Health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12months of immunoglobulin G treatment","volume":"36","author":"Routes","year":"2016","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.intimp.2016.12.030_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/TCRM.S22599","article-title":"Human normal immunoglobulin in the treatment of primary immunodeficiency diseases","volume":"8","author":"Wood","year":"2012","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.intimp.2016.12.030_bb0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7525-3-31","article-title":"Coping, quality of life, and hope in adults with primary antibody deficiencies","volume":"3","author":"Sigstad","year":"2005","journal-title":"Health Qual. Life Outcomes."},{"key":"10.1016\/j.intimp.2016.12.030_bb0105","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/PPA.S60771","article-title":"Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment","volume":"8","author":"Espanol","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.intimp.2016.12.030_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3111\/13696998.2012.716804","article-title":"Patient and parent preferences for immunoglobulin treatments: a conjoint analysis","volume":"15","author":"Mohamed","year":"2012","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.intimp.2016.12.030_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12026-011-8241-y","article-title":"Global study of primary immunodeficiency diseases (PI)\u2014diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation","volume":"51","author":"Modell","year":"2011","journal-title":"Immunol. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2016.12.030_bb0120","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/trf.13159","article-title":"Polyvalent immune globulin usage by indication in the United States, 2012: a quantitative analysis of the use of polyvalent immune globulin (intravenous and subcutaneous) by medical indication in the United States in 2012","volume":"55","author":"Robert","year":"2015","journal-title":"Transfusion"},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2016.12.030_bb0125","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/01.all.0000433131.08813.66","article-title":"Pharmacoeconomics of immunoglobulins and indications for their use","volume":"13","author":"Guillevin","year":"2013","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2016.12.030_bb0130","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1007\/s10875-012-9838-1","article-title":"Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease","volume":"33","author":"Bonagura","year":"2013","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2016.12.030_bb0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.aller.2012.09.006","article-title":"Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America","volume":"42","author":"Condino-Neto","year":"2014","journal-title":"Allergol Immunopathol (Madr)"}],"updated-by":[{"DOI":"10.1016\/j.intimp.2017.10.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000}}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691630532X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691630532X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T07:25:43Z","timestamp":1536132343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757691630532X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":27,"alternative-id":["S156757691630532X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2016.12.030","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.intimp.2017.10.014","asserted-by":"object"}]},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid infusions of human normal immunoglobulin 50g\/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2016.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}